NCT04550494
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 121 versions: 3 with changes below, 47 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Study completion pushed from Jul 27, 2027 to Oct 22, 2027
- Minor Study completion date: Jul 14, 2027 to Jul 27, 2027v117
- Minor Trial status changed: Recruiting → Active, Not Recruiting
- Enrollment reduced: 36 → 29 participants
- Primary completion moved earlier from Dec 1, 2026 to Jul 10, 2026
- Study completion pushed from Dec 1, 2026 to Jul 14, 2027
- Minor: routine updates
Endpoints
Primary
Percent of patients who demonstrate simultaneous Rad51 activation
Timeframe: At cycle 2 day 1
Secondary (1)
Overall response rate
Arms and interventions
Treatment (talazoparib)Experimental
Patients receive talazoparib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo biopsy and blood sample collection as well as CT scan or MRI throughout the study.
Procedures: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Drugs: Talazoparib
Sites
4 sites in 1 country